Compare Quest Diagnostics Inc (DGX) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Jumia Technologies AG - ADR — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Jumia Technologies AG - ADR trades at $6.28 (market cap $865.90M). The key difference: Quest Diagnostics Inc is far larger — about 29.4× Jumia Technologies AG - ADR's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Jumia Technologies AG - ADR for 28 Days on average.
| DGX | JMIA | |
|---|---|---|
Market Cap | $25.48B | $865.90M |
Volume | 941,866 | 1,695,227 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $14.60 |
52-Week Low | $173.49 | $5.69 |
Typical Hold Time | 56 Days | 28 Days |
Enterprise Value | $31.23B | $831.54M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
JMIA stock trades at $6.48, down 3.86% today, with a bearish technical outlook from moving averages. The company reported Q2 2026 revenue growth and narrowing losses, with a path to EBITDA breakeven by Q4 2026. Analyst consensus is bullish with a $12.00 price target, but the stock faces headwinds from persistent negative earnings and high valuation multiples.
The investment case hinges on JMIA's operational improvements and capital infusion, but risks include sustained cash burn and competitive pressures in African e-commerce. Upside potential exists if profitability targets are met, yet the stock remains speculative given its financial losses and volatile trading pattern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
